High-Yield Generic Drug Manufacturing Portfolio

Ensuring affordable access to essential medicines is a cornerstone of healthcare stability in Southeast Asia. Our Generic Drug Manufacturing Portfolio focuses on scaling production capabilities and enhancing the quality standards of local manufacturers to reduce reliance on expensive imports and improve regional health security.

API Production

Investing in the local synthesis of Active Pharmaceutical Ingredients to secure the supply chain.

Biosimilar Development

Scaling the production of complex biological generics to make advanced therapies affordable.

GMP Facility Upgrades

Funding the transition to WHO-standard Good Manufacturing Practices for global export readiness.

Specialized Formulation

Developing innovative delivery systems for generic drugs to improve patient adherence.

Optimizing the Value Chain

The transition from small-batch production to industrial-scale manufacturing requires significant capital expenditure and operational expertise. We specialize in optimizing the manufacturing lifecycle, from raw material sourcing to final packaging. For a detailed look at our current holdings, visit our full Investment Portfolio.

Implementation of Lean Manufacturing and Six Sigma methodologies.
Strategic partnerships with regional health ministries for procurement contracts.
Investment in automated quality control and real-time monitoring systems.
Expansion of cold-chain logistics for temperature-sensitive generics.

We focus on therapeutic areas with high unmet needs, including anti-infectives, cardiovascular drugs, and metabolic disorder treatments.

For entrepreneurs looking to scale their facilities, our Funding Guides offer a roadmap for securing the capital necessary for industrial expansion.